Form: 3/A

Initial statement of beneficial ownership of securities

October 14, 2021

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Ghoshal Kaushik
(Last) (First) (Middle)
RESMED INC.
9001 SPECTRUM CENTER BLVD.
(Street)
SAN DIEGO CA 92123
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
08/25/2021 		3. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President, SaaS Business
 5. If Amendment, Date of Original Filed (Month/Day/Year)
09/07/2021
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
ResMed Common Stock 7,370 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
ResMed Common Stock Options 04/02/2018 04/02/2025 ResMed Common Stock 2,086(1) 95.8 D
ResMed Common Stock Options 11/21/2019 11/21/2026 ResMed Common Stock 683 146.34 D
ResMed Common Stock Options 11/19/2020 11/19/2027 ResMed Common Stock 472 211.76 D
ResMed Common Stock Options 04/02/2018 04/02/2025 ResMed Common Stock 6,877 95.8 D
ResMed Common Stock Options 11/14/2018 11/14/2025 ResMed Common Stock 10,297 101.64 D
ResMed Common Stock Options 11/21/2019 11/21/2026 ResMed Common Stock 7,095 146.34 D
ResMed Common Stock Options 11/19/2020 11/19/2027 ResMed Common Stock 10,608 211.76 D
Explanation of Responses:
1. Corrects the number of outstanding options as of September 1, 2021.
Kaushik Ghoshal, President SaaS Business 10/13/2021
** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.